Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Alterations of the bile microbiome in primary sclerosing cholangitis.

Liwinski T, Zenouzi R, John C, Ehlken H, Rühlemann MC, Bang C, Groth S, Lieb W, Kantowski M, Andersen N, Schachschal G, Karlsen TH, Hov JR, Rösch T, Lohse AW, Heeren J, Franke A, Schramm C.

Gut. 2019 Jun 26. pii: gutjnl-2019-318416. doi: 10.1136/gutjnl-2019-318416. [Epub ahead of print]

PMID:
31243055
2.

Rate of Spleen Length Progression Is a Marker of Outcome in Patients With Primary Sclerosing Cholangitis.

Jung F, Cazzagon N, Vettorazzi E, Corpechot C, Chazouilleres O, Arrivé L, Lohse AW, Schramm C, Ehlken H.

Clin Gastroenterol Hepatol. 2019 Nov;17(12):2613-2615. doi: 10.1016/j.cgh.2018.12.033. Epub 2019 Jan 4.

PMID:
30616025
3.

Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis.

Peiseler M, Reiners D, Pinnschmidt HO, Sebode M, Jung F, Hartl J, Zenouzi R, Ehlken H, Groth S, Schachschal G, Rösch T, Weiler-Normann C, Lohse AW, Schramm C.

PLoS One. 2018 Aug 20;13(8):e0202686. doi: 10.1371/journal.pone.0202686. eCollection 2018.

4.

Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure.

Zenouzi R, von der Gablentz J, Heldmann M, Göttlich M, Weiler-Normann C, Sebode M, Ehlken H, Hartl J, Fellbrich A, Siemonsen S, Schramm C, Münte TF, Lohse AW.

PLoS One. 2018 Jan 10;13(1):e0190005. doi: 10.1371/journal.pone.0190005. eCollection 2018.

5.

Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis.

Hartl J, Ehlken H, Sebode M, Peiseler M, Krech T, Zenouzi R, von Felden J, Weiler-Normann C, Schramm C, Lohse AW.

J Hepatol. 2018 Apr;68(4):754-763. doi: 10.1016/j.jhep.2017.11.020. Epub 2017 Nov 24.

PMID:
29180000
6.

Risk of cholangiocarcinoma in patients with primary sclerosing cholangitis: diagnosis and surveillance.

Ehlken H, Zenouzi R, Schramm C.

Curr Opin Gastroenterol. 2017 Mar;33(2):78-84. doi: 10.1097/MOG.0000000000000335. Review.

PMID:
28146445
7.

Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune Hepatitis.

Peiseler M, Liebscher T, Sebode M, Zenouzi R, Hartl J, Ehlken H, Pannicke N, Weiler-Normann C, Lohse AW, Schramm C.

Clin Gastroenterol Hepatol. 2018 Feb;16(2):260-267.e1. doi: 10.1016/j.cgh.2016.12.040. Epub 2017 Jan 23.

PMID:
28126427
8.

No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis.

Zenouzi R, Weismüller TJ, Jørgensen KK, Bubenheim M, Lenzen H, Hübener P, Schulze K, Weiler-Normann C, Sebode M, Ehlken H, Pannicke N, Hartl J, Peiseler M, Hübener S, Karlsen TH, Boberg KM, Manns MP, Lohse AW, Schramm C.

Clin Gastroenterol Hepatol. 2016 Dec;14(12):1806-1812. doi: 10.1016/j.cgh.2016.07.032. Epub 2016 Aug 10.

PMID:
27521513
9.

Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis.

Ehlken H, Wroblewski R, Corpechot C, Arrivé L, Rieger T, Hartl J, Lezius S, Hübener P, Schulze K, Zenouzi R, Sebode M, Peiseler M, Denzer UW, Quaas A, Weiler-Normann C, Lohse AW, Chazouilleres O, Schramm C.

PLoS One. 2016 Oct 10;11(10):e0164224. doi: 10.1371/journal.pone.0164224. eCollection 2016.

10.

Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis.

Hartl J, Denzer U, Ehlken H, Zenouzi R, Peiseler M, Sebode M, Hübener S, Pannicke N, Weiler-Normann C, Quaas A, Lohse AW, Schramm C.

J Hepatol. 2016 Oct;65(4):769-775. doi: 10.1016/j.jhep.2016.05.023. Epub 2016 May 26.

PMID:
27238753
11.

Opposing role of tumor necrosis factor receptor 1 signaling in T cell-mediated hepatitis and bacterial infection in mice.

Wroblewski R, Armaka M, Kondylis V, Pasparakis M, Walczak H, Mittrücker HW, Schramm C, Lohse AW, Kollias G, Ehlken H.

Hepatology. 2016 Aug;64(2):508-21. doi: 10.1002/hep.28551. Epub 2016 Apr 18.

PMID:
26991125
12.

Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis.

Ehlken H, Wroblewski R, Corpechot C, Arrivé L, Lezius S, Hartl J, Denzer UW, Lohse AW, Chazouilleres O, Schramm C.

Gut. 2016 Jul;65(7):1230-2. doi: 10.1136/gutjnl-2016-311452. Epub 2016 Feb 26. No abstract available.

PMID:
26921347
13.

NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis.

Kondylis V, Polykratis A, Ehlken H, Ochoa-Callejero L, Straub BK, Krishna-Subramanian S, Van TM, Curth HM, Heise N, Weih F, Klein U, Schirmacher P, Kelliher M, Pasparakis M.

Cancer Cell. 2015 Dec 14;28(6):830. doi: 10.1016/j.ccell.2015.11.007. Epub 2015 Dec 14. No abstract available.

14.

NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis.

Kondylis V, Polykratis A, Ehlken H, Ochoa-Callejero L, Straub BK, Krishna-Subramanian S, Van TM, Curth HM, Heise N, Weih F, Klein U, Schirmacher P, Kelliher M, Pasparakis M.

Cancer Cell. 2015 Nov 9;28(5):582-598. doi: 10.1016/j.ccell.2015.10.001. Erratum in: Cancer Cell. 2015 Dec 14;28(6):830.

15.

Acute and Chronic Inflammation of the Biliary System.

Lankisch Chair T, Bektas H, Dechêne A, Ehlken H, Kirchner GI, Lang H, Schramm C.

Viszeralmedizin. 2015 Jun;31(3):200-3. doi: 10.1159/000434663. Epub 2015 Jun 15. No abstract available.

16.

How Should Cancer Surveillance in Primary Sclerosing Cholangitis Be Performed?

Ehlken H, Schramm C.

Viszeralmedizin. 2015 Jun;31(3):173-7. doi: 10.1159/000431350. Epub 2015 Jun 9. Review.

17.

Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis.

Hartl J, Ehlken H, Weiler-Normann C, Sebode M, Kreuels B, Pannicke N, Zenouzi R, Glaubke C, Lohse AW, Schramm C.

J Hepatol. 2015 Mar;62(3):642-6. doi: 10.1016/j.jhep.2014.10.018. Epub 2014 Oct 18.

PMID:
25457202
18.

Transient elastography in primary sclerosing cholangitis-the value as a prognostic factor and limitations.

Ehlken H, Lohse AW, Schramm C.

Gastroenterology. 2014 Aug;147(2):542-3. doi: 10.1053/j.gastro.2014.04.058. Epub 2014 Jun 25. No abstract available.

PMID:
24973676
19.

Death receptor-independent FADD signalling triggers hepatitis and hepatocellular carcinoma in mice with liver parenchymal cell-specific NEMO knockout.

Ehlken H, Krishna-Subramanian S, Ochoa-Callejero L, Kondylis V, Nadi NE, Straub BK, Schirmacher P, Walczak H, Kollias G, Pasparakis M.

Cell Death Differ. 2014 Nov;21(11):1721-32. doi: 10.1038/cdd.2014.83. Epub 2014 Jun 27.

20.

PSC: Novel disease associations providing pathogenetic clues?

Ehlken H, Schramm C.

J Hepatol. 2014 Apr;60(4):687-8. doi: 10.1016/j.jhep.2014.01.005. Epub 2014 Jan 14. No abstract available.

21.

Primary sclerosing cholangitis and cholangiocarcinoma: pathogenesis and modes of diagnostics.

Ehlken H, Schramm C.

Dig Dis. 2013;31(1):118-25. doi: 10.1159/000347206. Epub 2013 Jun 17. Review.

PMID:
23797133
22.

c-FLIP maintains tissue homeostasis by preventing apoptosis and programmed necrosis.

Piao X, Komazawa-Sakon S, Nishina T, Koike M, Piao JH, Ehlken H, Kurihara H, Hara M, Van Rooijen N, Schütz G, Ohmuraya M, Uchiyama Y, Yagita H, Okumura K, He YW, Nakano H.

Sci Signal. 2012 Dec 18;5(255):ra93. doi: 10.1126/scisignal.2003558.

23.

Hepatocyte IKK2 protects Mdr2-/- mice from chronic liver failure.

Ehlken H, Kondylis V, Heinrichsdorff J, Ochoa-Callejero L, Roskams T, Pasparakis M.

PLoS One. 2011;6(10):e25942. doi: 10.1371/journal.pone.0025942. Epub 2011 Oct 14.

24.

Supplemental Content

Loading ...
Support Center